AlphaQuest LLC Purchases 262 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AlphaQuest LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,236 shares of the biopharmaceutical company’s stock after purchasing an additional 262 shares during the period. AlphaQuest LLC’s holdings in Regeneron Pharmaceuticals were worth $1,593,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Concurrent Investment Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 3.6% in the third quarter. Concurrent Investment Advisors LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $906,000 after acquiring an additional 30 shares during the last quarter. Portside Wealth Group LLC increased its position in shares of Regeneron Pharmaceuticals by 14.7% in the third quarter. Portside Wealth Group LLC now owns 724 shares of the biopharmaceutical company’s stock valued at $761,000 after acquiring an additional 93 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $298,000. Windward Capital Management Co. CA acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $420,000. Finally, Assetmark Inc. increased its position in shares of Regeneron Pharmaceuticals by 8.7% in the third quarter. Assetmark Inc. now owns 103,980 shares of the biopharmaceutical company’s stock valued at $109,308,000 after acquiring an additional 8,289 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on REGN. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Sanford C. Bernstein lowered their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Finally, Bernstein Bank lowered their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ:REGN opened at $707.51 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a market cap of $77.35 billion, a PE ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27. The business has a 50 day moving average of $696.12 and a 200-day moving average of $851.05. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $11.86 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.